R. Mouawad et al., STUDY OF IL-2 RECEPTOR EXPRESSION AFTER CHEMOIMMUNOTHERAPY IN PATIENTS TREATED FOR METASTATIC MALIGNANT-MELANOMA, Clinical and experimental immunology, 97(3), 1994, pp. 342-346
Using flow cytometry, cellular IL-2 receptors were studied before and
following chemoimmunotherapy combination in 20 patients with metastati
c malignant melanoma (MMM). Patients received cisplatin (100 mg/m(2))
at days 1 and 28, recombinant IL-2 by continuous infusion from days 3
to 6, 17 to 21, 31 to 34, and 45 to 49. Interferon-alpha (IFN-alpha) w
as given subcutaneously three times weekly. In terms of clinical respo
nse, we observed 55% objective response (complete: 15%). When pretreat
ment blood samples were compared with those of healthy donors, we did
not observe any change in low (alpha chain) and high affinity receptor
(alpha+beta) expression. In contrast, intermediate affinity p75 (beta
chain) expression was decreased significantly (P less than or equal t
o 0.0001) in MMM patients. During treatment, we found a dramatic incre
ase of beta chain as well as high affinity (alpha+beta) expression in
responding patients, as soon as IL-2 therapy began. Furthermore, the i
ncrease of beta chain expression was limited to natural killer (NK) ce
lls (CD56(+)). In non-responding patients, on the other hand, increase
of both receptors was seen only at day 31. These data suggest the inv
olvement of beta chain expression in the mechanism of cell activation
after chemoimmunotherapy. Moreover, this early beta chain expression i
s correlated with the clinical response to chemoimmunotherapy.